1383816-29-2

Basic information

• Product Name: Tropifexor
• Synonyms: Tropifexor;Tropifexor (LJN452);LJN452;LJN452,Tropifexor;2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid;1383816-29-2
• CAS NO: 1383816-29-2
• Molecular Formula: C₂₉H₂₅F₄N₃O₅S
• Molecular Weight: 603.5845128
• EINECS: -0
• Product Categories: API
• Mol File: 1383816-29-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 700.0±65.0 °C(Predicted)
• Appearance: /
• Density: 1.55±0.1 g/cm3(Predicted)
• PKA: 3.84±0.10(Predicted)
• CAS DataBase Reference: Tropifexor(CAS DataBase Reference)
• NIST Chemistry Reference: Tropifexor(1383816-29-2)
• EPA Substance Registry System: Tropifexor(1383816-29-2)

Safety Data

• Hazardous Substances Data: 1383816-29-2(Hazardous Substances Data)

Usage

Uses

Tropifexor, is a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH).

Upstream product

• 946427-86-7 4-(bromomethyl)-5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole 
• 1103500-32-8 methyl 5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole-4-carboxylate 
• 1383740-00-8 (E)-2-(trifluoromethoxy)benzaldehyde oxime 
• 1383740-01-9 (Z)-N-hydroxy-2-(trifluoromethoxy)benzimidoyl chloride 
• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 1383816-28-1 methyl-2-(3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-4-fluorobenzo[d]thiazole-6-carboxylate 
• 1383822-31-8 (1R,3S,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octane 
• 924287-65-0 methyl 2-bromo-4-fluoro-1,3-benzothiazole-6-carboxylate 
• 543713-03-7 N-hydroxy-2-(trifluoromethoxy)benzimidonyl chloride 
• 924287-64-9 methyl 2-amino-4-fluoro-1,3-benzothiazole-6-carboxylate 
• 185629-32-7 methyl 4-amino-3-fluorobenzene carboxylate 
• 185629-31-6 methyl 3-fluoro-4-nitrobenzoate 
• 94651-33-9 2-(trifluoromethoxy)benzaldehyde 

Downstream Products

• 1383816-38-3 C₂₉H₂₆F₄N₄O₄S 

Relevant articles and documents

COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES

In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.

COMPOSITIONS AND METHODS FOR MODULATING FXR

The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).